Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, everolimus (Certican®) cannot be endorsed for use within NHS Wales for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a cardiac transplant. |
||
|
||
Medicine details |
||
| Medicine name | everolimus (Certican®) | |
| Formulation | 0.25 mg, 0.50 mg, 0.75 mg and 1.0 mg tablet | |
| Reference number | 436 | |
| Indication | Prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a cardiac transplant |
|
| Company | Novartis Pharmaceuticals UK Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 15/05/2015 | |